Heineken warns pubs to adapt to weight-loss drug trends
by@Reuters
Summary
Heineken has issued a warning to British pubs and bars about the potential negative impact of weight-loss drugs on beer sales, highlighting that the surge in the use of GLP-1 medications could lead to decreased customer demand for alcohol. The company noted that around 10 million people in the US were using these drugs last year, which have been shown to reduce cravings for alcohol, resulting in consumers opting for smaller serves or lower-alcohol options. Heineken's presentation advised hospitality venues to adapt by promoting half-pints and no-alcohol drinks to maintain customer visits and spending, amidst a backdrop of declining alcohol consumption as more individuals embrace moderation in drinking habits.
Tokens
$HEIA$NOVO$DGE$ABI
Analysis
Diageo: Diageo is a leading spirits producer with a portfolio of alcoholic beverages. It has communicated to investors that any effects from GLP-1 drugs on consumption should remain manageable even with wider adoption. Heineken: Heineken is a major global brewer focused on producing and distributing beer and cider brands. In this news, the company has shared a presentation with UK hospitality venues advising them to adapt offerings like half-pints and low-alcohol drinks due to shifts in consumption linked to GLP-1 medications. Lisa Jucca: Lisa Jucca is a Reuters editor involved in overseeing the editing of this article on Heineken and GLP-1 drug impacts. Emma Rumney: Emma Rumney is a Reuters journalist who reported this exclusive story on Heineken's internal presentation regarding weight-loss drugs and alcohol sales. Novo Nordisk: Novo Nordisk is a pharmaceutical company known for developing and marketing GLP-1 receptor agonist medications such as Ozempic and Wegovy. The news highlights these products as central to the surge in weight-loss drug use that Heineken identifies as a potential factor in reduced alcohol demand. Joseph Schacht: Joseph Schacht is a professor at the University of Colorado Anschutz who has led research on GLP-1 medications and alcohol use disorder. He notes consistent findings of reduced cravings and consumption in trials, highlighting broader implications for the alcohol industry. Daniel Cornwell: Daniel Cornwell is the founder of hospitality executive recruitment firm SPE Resourcing and a GLP-1 user who has shared his experience of reduced alcohol tolerance and discomfort after drinking. Elaine Hardcastle: Elaine Hardcastle is a Reuters editor who contributed to the editing of this exclusive report. Anheuser-Busch InBev: Anheuser-Busch InBev is the world's largest brewer by volume with extensive global operations. The company has declined to comment on the potential influence of GLP-1 medications on beer sales trends. Consumer Trends: GLP-1 users report opting for smaller or no alcohol servings due to feelings of fullness or lack of desire, aligning with wider moderation patterns in drinking. Industry Response: Major alcohol companies are monitoring shifts in consumer behavior among GLP-1 users and positioning portfolios toward smaller serves, lower-alcohol options, and premium products. Research Findings: Clinical trials have shown GLP-1 medications can reduce alcohol cravings and consumption, with potential applications in treating alcohol use disorder.
Categories
macro